Soligenix gets additional NIAID funding to advance development of OrbeShield in GI ARS
The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield™ as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS).